674 related articles for article (PubMed ID: 11518967)
21. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.
Chen G; Shukeir N; Potti A; Sircar K; Aprikian A; Goltzman D; Rabbani SA
Cancer; 2004 Sep; 101(6):1345-56. PubMed ID: 15316903
[TBL] [Abstract][Full Text] [Related]
22. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
23. GREB1 tissue expression is associated with organ-confined prostate cancer.
Antunes AA; Leite KR; Reis ST; Sousa-Canavez JM; Camara-Lopes LH; Dall'oglio MF; Srougi M
Urol Oncol; 2012; 30(1):16-20. PubMed ID: 19945309
[TBL] [Abstract][Full Text] [Related]
24. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions.
Merseburger AS; Hennenlotter J; Simon P; Müller CC; Kühs U; Knüchel-Clarke R; Moul JW; Stenzl A; Kuczyk MA
Oncol Rep; 2006 Jul; 16(1):79-83. PubMed ID: 16786126
[TBL] [Abstract][Full Text] [Related]
25. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray.
Xu J; Stolk JA; Zhang X; Silva SJ; Houghton RL; Matsumura M; Vedvick TS; Leslie KB; Badaro R; Reed SG
Cancer Res; 2000 Mar; 60(6):1677-82. PubMed ID: 10749139
[TBL] [Abstract][Full Text] [Related]
26. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation.
Halvorsen OJ; Oyan AM; Bø TH; Olsen S; Rostad K; Haukaas SA; Bakke AM; Marzolf B; Dimitrov K; Stordrange L; Lin B; Jonassen I; Hood L; Akslen LA; Kalland KH
Int J Oncol; 2005 Feb; 26(2):329-36. PubMed ID: 15645116
[TBL] [Abstract][Full Text] [Related]
28. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
[TBL] [Abstract][Full Text] [Related]
29. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
30. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model.
Diallo JS; Aldejmah A; Mouhim AF; Péant B; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
Clin Cancer Res; 2007 Dec; 13(23):7044-52. PubMed ID: 18056181
[TBL] [Abstract][Full Text] [Related]
31. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
[TBL] [Abstract][Full Text] [Related]
32. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
Stamey TA; Warrington JA; Caldwell MC; Chen Z; Fan Z; Mahadevappa M; McNeal JE; Nolley R; Zhang Z
J Urol; 2001 Dec; 166(6):2171-7. PubMed ID: 11696729
[TBL] [Abstract][Full Text] [Related]
33. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.
Fu Z; Kitagawa Y; Shen R; Shah R; Mehra R; Rhodes D; Keller PJ; Mizokami A; Dunn R; Chinnaiyan AM; Yao Z; Keller ET
Prostate; 2006 Feb; 66(3):248-56. PubMed ID: 16175585
[TBL] [Abstract][Full Text] [Related]
34. [Expression of PIM-1 in prostate cancer tissue and its relationship with PSA recurrence].
Zhang CT; Xu Y; Luo F; Zhang ZH; Liu RL; Yang K; Ma BJ
Zhonghua Nan Ke Xue; 2012 Apr; 18(4):323-6. PubMed ID: 22574367
[TBL] [Abstract][Full Text] [Related]
35. Down-regulated expression of prostasin in high-grade or hormone-refractory human prostate cancers.
Takahashi S; Suzuki S; Inaguma S; Ikeda Y; Cho YM; Hayashi N; Inoue T; Sugimura Y; Nishiyama N; Fujita T; Chao J; Ushijima T; Shirai T
Prostate; 2003 Feb; 54(3):187-93. PubMed ID: 12518323
[TBL] [Abstract][Full Text] [Related]
36. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW
Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962
[TBL] [Abstract][Full Text] [Related]
37. Expression screening of cancer/testis genes in prostate cancer identifies NR6A1 as a novel marker of disease progression and aggressiveness.
Mathieu R; Evrard B; Fromont G; Rioux-Leclercq N; Godet J; Cathelineau X; Guillé F; Primig M; Chalmel F
Prostate; 2013 Jul; 73(10):1103-14. PubMed ID: 23532770
[TBL] [Abstract][Full Text] [Related]
38. Spotting prostate cancer.
Neill GW; Kelsell DP
Trends Mol Med; 2001 Oct; 7(10):432. PubMed ID: 11597508
[No Abstract] [Full Text] [Related]
39. Pim-3 is a Critical Risk Factor in Development and Prognosis of Prostate Cancer.
Qu Y; Zhang C; Du E; Wang A; Yang Y; Guo J; Wang A; Zhang Z; Xu Y
Med Sci Monit; 2016 Nov; 22():4254-4260. PubMed ID: 27826135
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth.
Bindukumar B; Schwartz SA; Nair MP; Aalinkeel R; Kawinski E; Chadha KC
Neoplasia; 2005 Mar; 7(3):241-52. PubMed ID: 15799824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
